Analysis of etodolac and diclofenac in pure and pharmaceutical forms using ionic-liquid dispersive liquid–liquid microextraction and RP-HPLC technique

In this research, etodolac and diclofenac were determined using ionic-liquid dispersive liquid–liquid microextraction (IL-DLLME), followed by dilution/back-extraction with ethanol, and then analyzed by reversed-phase high-performance liquid chromatography (RP-HPLC). Each drug was measured at ۲۷۴nm and ۲۷۹nm for Diclofenac (DIC) and Etodolac (ETO), respectively. Beer's law was obeyed in the linear ranges of ۰.۶-۲۰ µg mL-۱ for Diclofenac sodium (r = ۰.۹۹۹) and ۰.۵-۳۵ µg mL-۱ for etodolac (r = ۰.۹۹۷). The relative standard deviation (RSD%) and detection limit were ۱.۶۲۳% and ۰.۱۰۲ µg mL-۱ for Diclofenac, and ۱.۶۰۷% and ۰.۰۹۸ µg mL-۱ for Etodolac. The chromatographic system consists of an HPLC equipped with a C۱۸ column (۲۵۰ mm x ۴.۶ mm). The mobile phase consisted of methanol/acetonitrile: phosphate buffer (pH=۵-۶) in the ratio of ۵۵:۴۵ v/v at a flow rate of ۱.۰ mL min-۱. This method has been successfully applied to determine diclofenac and etodolac, which is a cost-effective and straightforward method that allows the simultaneous analysis in tablet dosage forms in pharmaceutical formulations, where the error and recovery ratios for diclofenac (۱۰۰ mg) were obtained at ۴.۱۷%, ۹۵.۸۳%, and etodolac (۴۰۰ mg), ۳.۲۵%, ۹۶.۷۵%, respectively. RP-HPLC methods based on ionic liquid extraction exhibit high sensitivity, linearity, and repeatability for the detection of etodolac and diclofenac in their pure and pharmaceutical forms.

کلیدواژه ها:

Etodolac and Diclofenac ، Ionic-liquid ، Dispersive liquid liquid microextraction ، Reversed-phase high performance liquid chromatography ، Tablet form